{"id":"E17","lang":"en","question":"What are the disclosed terms of the BioNTech and DualityBio ADC licensing deal?","answer":[{"text":"For the two-asset partnership announced on April 3, 2023, DualityBio disclosed US$170 million upfront, more than US$1.5 billion in potential milestones and single-digit to double-digit tiered royalties.","fact_ids":["f1","f2","f3"]},{"text":"That agreement covered DB-1303 and DB-1311, with BioNTech holding commercial rights outside Mainland China, Hong Kong and Macau.","fact_ids":["f4"]},{"text":"BioNTech’s 2023 annual report subsequently included the August DB-1305 agreement and reported US$220 million in combined Duality upfront payments.","fact_ids":["f5"]}],"facts":[{"id":"f1","claim":"April 2023 upfront","value":"USD 170,000,000 for DB-1303 and DB-1311 together","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"$170 million"},{"id":"f2","claim":"April 2023 potential milestones","value":"Over USD 1,500,000,000","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"over $1.5 billion"},{"id":"f3","claim":"April 2023 royalty range","value":"Single-digit to double-digit tiered royalties","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"single-digit to double-digit"},{"id":"f4","claim":"Assets and territory","value":"DB-1303 and DB-1311; BioNTech rights outside Mainland China, Hong Kong and Macau","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"DB-1303 and DB-1311"},{"id":"f5","claim":"2023 combined upfront after third ADC","value":"USD 220,000,000; includes DB-1305 agreement signed in August 2023","as_of":"2023-12-31","source":"https://www.biontech.com/content/dam/corporate/pdf/BioNTech_GB23_EN_Online.pdf","quote":"$220.0 million"}],"undisclosed":{"text":"The checked public announcements and annual report do not disclose the exact royalty percentages at every tier or allocate all upfront amounts by individual asset.","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","as_of":"2026-10-22","quote":"tiered royalties","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["April two-asset deal and later three-asset aggregate are separated; precise royalty tiers remain undisclosed."]}